ATI Pathophysiology Final Exam Related

Review ATI Pathophysiology Final Exam related questions and content

A patient with a history of osteoporosis is prescribed raloxifene (Evista). What is the primary therapeutic effect of this medication?

  • A. It stimulates the formation of new bone.
  • B. It decreases bone resorption and increases bone density.
  • C. It increases calcium absorption in the intestines.
  • D. It increases the excretion of calcium through the kidneys.
Correct Answer: B

Rationale: The correct answer is B. Raloxifene, such as Evista, works by decreasing bone resorption and increasing bone density. This medication is beneficial in the prevention and treatment of osteoporosis by slowing down the breakdown of bone tissue, thereby reducing the risk of fractures. Choices A, C, and D are incorrect because raloxifene does not directly stimulate the formation of new bone, increase calcium absorption in the intestines, or increase the excretion of calcium through the kidneys.